Published in FASEB J on May 02, 2013
Nongenomic actions of thyroid hormone. Nat Rev Endocrinol (2015) 0.92
Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac. Front Endocrinol (Lausanne) (2015) 0.86
The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene (2015) 0.83
Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Best Pract Res Clin Endocrinol Metab (2015) 0.82
Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget (2015) 0.80
Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent? Horm Cancer (2014) 0.78
Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther (2014) 0.78
Actions of Thyroid Hormone Analogues on Chemokines. J Immunol Res (2016) 0.75
Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 3.29
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology (2005) 2.34
Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease. Saudi J Kidney Dis Transpl (2015) 1.96
Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology (2005) 1.83
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
Role of RhoA-specific guanine exchange factors in regulation of endomitosis in megakaryocytes. Dev Cell (2012) 1.76
Serum response factor is an essential transcription factor in megakaryocytic maturation. Blood (2010) 1.65
Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab (2009) 1.56
Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr (2012) 1.44
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol (2009) 1.43
Relevance of the thyroid hormones-αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action. Leuk Lymphoma (2014) 1.43
Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol (2007) 1.43
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res (2009) 1.40
The double-edged sword of the immune system--a force for good or evil in the wound? Int Wound J (2009) 1.38
The factors influencing transactional sex among young men and women in 12 sub-Saharan African countries. Soc Biol (2007) 1.36
Endosymbiont DNA in endobacteria-free filarial nematodes indicates ancient horizontal genetic transfer. PLoS One (2010) 1.33
Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res (2004) 1.28
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood (2003) 1.27
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res (2006) 1.25
The MspJI family of modification-dependent restriction endonucleases for epigenetic studies. Proc Natl Acad Sci U S A (2011) 1.25
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine (2009) 1.25
Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro. J Biol Chem (2006) 1.23
Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. Cell Biol Int (2008) 1.22
Computational prediction of essential genes in an unculturable endosymbiotic bacterium, Wolbachia of Brugia malayi. BMC Microbiol (2009) 1.22
Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther (2010) 1.22
Emerging nanopharmaceuticals. Nanomedicine (2008) 1.21
Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost (2003) 1.21
Metformin and neoplasia: implications and indications. Pharmacol Ther (2011) 1.20
Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J (2006) 1.19
The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A (2003) 1.18
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost (2007) 1.18
The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost (2007) 1.17
Identification of binding sites of EVI1 in mammalian cells. J Biol Chem (2005) 1.16
Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players. Steroids (2012) 1.15
Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab (2002) 1.15
Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules (2009) 1.12
Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol (2011) 1.12
Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology (2004) 1.12
High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res (2012) 1.12
Nongenomic actions of thyroid hormone on the heart. Thyroid (2002) 1.11
SENP1-mediated GATA1 deSUMOylation is critical for definitive erythropoiesis. J Exp Med (2010) 1.10
Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol (2002) 1.10
Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids (2006) 1.08
Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology (2009) 1.08
Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res (2003) 1.07
Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Lett (2007) 1.07
Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop (2011) 1.05
PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis (2008) 1.04
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol (2013) 1.03
Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab (2005) 1.02
Cloning and bioinformatic identification of small RNAs in the filarial nematode, Brugia malayi. Mol Biochem Parasitol (2009) 1.02
Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis (2007) 1.02
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) (2015) 1.02
Thyroid hormone and angiogenesis. Vascul Pharmacol (2009) 1.00
Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol (2009) 1.00
Evolution of bacterial phosphoglycerate mutases: non-homologous isofunctional enzymes undergoing gene losses, gains and lateral transfers. PLoS One (2010) 0.99
Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99
Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther (2006) 0.99
The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs (2002) 0.97
Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem (2006) 0.96
MKL1 and MKL2 play redundant and crucial roles in megakaryocyte maturation and platelet formation. Blood (2012) 0.96
Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle (2009) 0.96
Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One (2011) 0.96
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci (2014) 0.96
Thyroid hormones as modulators of immune activities at the cellular level. Thyroid (2011) 0.95